Skip to main content

approvalsWatch: Neurology 090516

US FDA Approvals

The US FDA has approved perampanel CIII Oral Suspension as a bioequivalent, interchangeable alternative to the tablet formulation. Perampanel is indicated as adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures, and primary generalized tonic–clonic seizures in patients with epilepsy aged 12 years or older.